2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2813

IL-17 Induces Skin Inflammation Independently of IL-23R+ T Cells and Is Protected By Conditional Deletion of Wdfy3 in Neutrophils

Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 3020

IL-21 Abrogates CD4+CD25+FOXP3+ Treg Differentiation in Part By Suppressing Treg GATA-3 Expression in SLE

T cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2761

IL-6R Blockade with Sarilumab Plus Methotrexate Results in Changes in Clinical and Laboratory Parameters Associated with Chronic Inflammation in Patients with Moderate-to-Severe RA in a Phase 3 Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2793

IL35 Serum Level Is Decreased in Patients with Primary Sjogren Syndrome, Essentially in Patients with the More Active Disease Data from the French Prospective Assess Cohort

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 2709

Immediate Release of Peripheral Neutrophil Myeloperoxidase and Elastase and Formation of Extracellular Traps to Cigarette Smoking in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2563

Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2210

Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2430

Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2702

Immunophenotyping of Rheumatoid Arthritis Reveals the Linkage Between HLA-DRB1 Genotype, CXCR4 Expressions on Memory CD4+ T Cells, and Disease Activity

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2612

Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2339

Impact of Abbvie’s Patient Support Program on Resource Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2343

Impact of Colchicine Use on the Development of Incident Coronary Artery Disease

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2500

Impact of Health Portal Enrollment and Electronic Appointment Reminders to Improve Appointment Attendance at an Academic Rheumatology Clinic

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2869

Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2650

Impact of Patient Education on the Satisfaction of Rheumatoid Arthritis Patient : A Randomized Trial of Nurse-Led Vs. Physician-Led Education

Rheumatoid Arthritis - Clinical Aspects Poster Session III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].